|
|
|
| Webinar: AI Reality Check in Drug Development: What’s Real and What’s Missing | AI is advancing drug discovery and development, but realizing its full potential depends on reliable, high-quality clinical data. Join Dr. Richard Graham, co-founder of TruTechnologies, and industry experts as they explore where AI is delivering value today, where challenges remain, and how sponsors can build the foundation for more effective AI-driven decisions across the drug development lifecycle. Click here to learn more. |
|
|
|
| How Regulatory Convergence Is Rewriting Clinical Data Management | Article | By Life Science Connect Editorial Staff | Regulatory shifts toward structured, digital clinical trial protocols are reducing manual interpretation, enabling risk-based oversight, and supporting more efficient, transparent, end-to-end trial execution. |
|
|
|
|
| Real-Time RTSM Integration Monitoring For Sponsors | Video | Korio | Real-time RTSM integration monitoring gives sponsors greater visibility, control, and confidence. Explore a platform that enables teams to manage the operational risks caused by this integration. |
|
|
|
|
|
| Patient organizations are moving beyond advisory roles to become active drivers of rare disease drug development. Join Craig Lipset and Dr. Derk Arts to explore how patient-led registries, natural-history data, real-world evidence, drug repurposing, and master protocols can help derisk clinical development. Discover what this emerging model looks like today, where its limits lie, and how clinical-development leaders can learn from early pioneers. Click here to learn more. |
|
|
CLINICAL DATA MANAGEMENT & ANALYTICS |
|
|
|
|
| Why AI Matters In Early Phase Clinical Trials | Article | CHDR | AI speeds early‑phase development by streamlining data review, enabling structured queries, accelerating PK/PD work, and revealing biomarker patterns — boosting efficiency with expert oversight. |
|
|
|
| Connect With Clinical Leader: |
|
|
|
